公开(公告)号：WO2023049162A1

公开(公告)日：2023-03-30

申请号：PCT/US2022/044221

申请日：2022-09-21

Applicant: BIOMEDIT, LLC

Inventor： SUSANTI, Dwi ,  KUMAR, Arvind ,  GANGAIAH, Dharanesh, Mahimapura

IPC: A61P31/04 ,  A61K38/17 ,  A61K38/04

Abstract: Provided are engineered polypeptides including CAP18 variants, and other engineered cathelicidin polypeptides based on BMAP28, BAC7, K9CATH and PMAP36. Also provided are methods for inhibiting growth of at least one methanogen in an animal. Further provided are methods of reducing greenhouse gas emissions, such as methane emissions, that use such compositions. The compositions and methods include one or more of the antimicrobial peptides including CAP 18 variants and other engineered cathelicidin polypeptides based on BMAP28, BAC7, K9CATH and PMAP36.

公开(公告)号：WO2023036842A1

公开(公告)日：2023-03-16

申请号：PCT/EP2022/074907

申请日：2022-09-07

Applicant: UNIVERSITE DE STRASBOURG ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

Inventor： BAGNARD, Dominique ,  BINAME, Fabien

IPC: A61K38/03 ,  A61K38/04 ,  A61P25/00 ,  A61P35/00

Abstract: The present application relates to peptides derived from the transmembrane domain of Plexin-A1 that inhibits Neuropilin-1/Plexin-A1 heterodimerization. These peptides neutralize the inhibitory effect of Sema3A on cell migration and angiogenesis, and may be useful for the treatment of diseases associated with Sema3A and/or Neuropilin-1/Plexin-A1 activity, such as demyelinating diseases and diseases associated with abnormal angiogenesis such as cancer.

公开(公告)号：WO2023023261A1

公开(公告)日：2023-02-23

申请号：PCT/US2022/040778

申请日：2022-08-18

Applicant: TRUSTEES OF TUFTS COLLEGE

Inventor： BACHOVCHIN, William W. ,  LAI, Hung-Sen ,  WU, Wengen

IPC: A61K31/69 ,  A61K38/04 ,  A61K51/04 ,  A61P35/00

Abstract: Disclosed are compounds useful for imaging cells that overexpress FAP, and for treating cancer. Also disclosed are methods of making said compounds.

公开(公告)号：WO2023017326A1

公开(公告)日：2023-02-16

申请号：PCT/IB2022/054963

申请日：2022-05-26

Applicant: RK PHARMA INC.

Inventor： KOVI, Ravishankar ,  KASU, Raghu Rami Reddy ,  REDDY, Thupalli Ajey Kumar ,  VAMSHI, Yekkanti ,  KANNAPPAN, Jayraman ,  CHAUHAN, Kamlesh

IPC: A61K38/08 ,  A61K38/04 ,  A61K31/00 ,  A61K47/08 ,  A61K47/12 ,  A61K47/00

Abstract: The present application discloses a ready-to-use liquid parenteral pharmaceutical composition, comprising Cetrorelix or Cetrorelix acetate.

公开(公告)号：WO2022261257A1

公开(公告)日：2022-12-15

申请号：PCT/US2022/032738

申请日：2022-06-08

Applicant: FOG PHARMACEUTICALS, INC.

Inventor： WHITE, Brian Halbert ,  LA, Daniel Seungduk ,  ALFARO-LOPEZ, Lorenzo Josue ,  ORTET, Paula Cristina ,  CAPPUCCI, Sarah Isabelle ,  LI, Zhi ,  MCGEE, John Hanney ,  TREMBLAY, Martin Robert ,  VERDINE, Gregory L. ,  SI, Yaguang ,  LING, Kevin ,  DU, Peicheng ,  HUROV, Jonathan Barry

IPC: A61K38/12 ,  A61K38/04 ,  A61P35/00 ,  C07K7/50 ,  C07K7/54 ,  C07K14/00

Abstract: Among other things, the present disclosure provides various useful agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids and agents which can provide improved properties and/or activities.

公开(公告)号：WO2022212513A1

公开(公告)日：2022-10-06

申请号：PCT/US2022/022559

申请日：2022-03-30

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： EVSEENKO, Denis ,  SHKHYAN, Ruzanna

IPC: A61K38/08 ,  A61P29/00 ,  A61K38/04 ,  A61K38/12 ,  A61P19/02 ,  A61K38/00

Abstract: The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation. The disclosure provides an isolated peptide comprising, consisting essentially of or consisting of 4-50 amino acids and containing the sequence QQ(PY)F, wherein the peptide interacts with c-SRC.

公开(公告)号：WO2022192877A1

公开(公告)日：2022-09-15

申请号：PCT/US2022/071038

申请日：2022-03-08

Applicant: BAYLOR COLLEGE OF MEDICINE

Inventor： WESTBROOK, Thomas F. ,  OLSON, Calla ,  KARLIN, Kristen

IPC: A61K38/04 ,  A61K38/00 ,  C12Q1/25 ,  C12Q1/68 ,  A61P35/00

Abstract: Embodiments of the disclosure concern identification of suitable inhibitors of components of RNA metabolism, including those involved with splicing, such as RNA helicases. The disclosure includes in vitro screens for small molecule inhibitors that are selective for a group of RNA helicases but that are counter-selective for another group of RNA helicases. In specific embodiments, the disclosure includes a system for inhibitor analysis that includes assay development and optimization that leads to feasible screening of the intended target(s) and continued counter-selection against undesirable targets throughout the process.

公开(公告)号：WO2022192450A2

公开(公告)日：2022-09-15

申请号：PCT/US2022/019621

申请日：2022-03-09

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Inventor： ACAR, Handan

IPC: A61K38/00 ,  A61K38/04 ,  B82Y5/00 ,  C40B40/10

Abstract: Compositions of anionic and cationic peptides which co-assemble under suitable conditions to form peptide nanostructures, methods of assembling the peptide nanostructures, and methods of use of the peptide nanostructures in hydrogels and as vaccines and vaccine adjuvants. The peptide nanostructures demonstrate stability once self-assembled and are biocompatible and have therapeutic functionality, particularly when equipped with additional functional features such as ligands, fluorophores, antigens, drugs, or other bioactive compounds.

公开(公告)号：WO2022184821A1

公开(公告)日：2022-09-09

申请号：PCT/EP2022/055387

申请日：2022-03-03

Applicant: VIB VZW ,  KATHOLIEKE UNIVERSITEIT LEUVEN

Inventor： SCHYMKOWITZ, Joost ,  ROUSSEAU, Frederic ,  KHODAPARAST, Ladan ,  KHODAPARAST, Laleh

IPC: C12N9/40 ,  A61K38/04 ,  C07K4/04 ,  C07K7/06 ,  C12N9/86 ,  C07K7/04

Abstract: The present invention relates to the field of microbiology, in particular to the field of bacterial antibiotic resistance, more particularly to the field of resistance to beta-lactam inhibitors. The invention provides non-natural compounds which induce the aggregation of beta-lactamases, particularly beta-lactamases of class A. In addition, the invention provides combination therapies and pharmaceutical compositions between the non-natural molecules and beta-lactam antibiotics.

公开(公告)号：WO2022165539A1

公开(公告)日：2022-08-04

申请号：PCT/US2022/070465

申请日：2022-02-01

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  SENS FOUNDATION, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： BARRON, Annelise, E. ,  RAE, Michael, J. ,  RASKATOV, Jevgenij ,  FORTKORT, John, A.

IPC: A61P25/28 ,  A61K38/04 ,  A61K31/19 ,  A61K31/185

Abstract: A method is provided for treating a subject suffering from a chronic infection that involves the brain. The chronic infection may range from those causing only mild cognitive impairment, to those present in individuals who have been diagnosed with Alzheimer's Disease. The method includes forming a composition containing (a) an anti-infective peptoid, and (b) a blood-brain barrier (BBB) manipulator that enhances the ability of the anti-infective peptoid to cross the BBB; and administering a therapeutic amount of the composition to a subject in need thereof.